I guess that's why they've refrained from making projections in recent years, because that one went awry.
Surely, this time they have better idea of future sales and its a more measured forecast. Afterall, Uscom 1A is in clinical guidelines now. Covid adds a new element as well, being relevant to the technology.
Directors buying is reassuring. In my experience the best sign of future success.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.759M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500000 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 46000 | 1 |
View Market Depth
| Last trade - 16.21pm 26/06/2025 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable